Schroder Investment Management Group
AVIR icon

Schroder Investment Management Group’s Atea Pharmaceuticals AVIR Stock Holding History

Schroder Investment Management Group’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-104,789
Closed -$742K – 1314
2022
Q1 		$742K Sell
104,789
-1,436,317
-93% -$9.75M ﹤0.01% 1172
2021
Q4 		$13.8M Buy
1,541,106
+1,525,824
+9,984% +$23.8M 0.02% 550
2021
Q3 		$536K Hold
15,282
– – ﹤0.01% 1197
2021
Q2 		$328K Sell
15,282
-12,043
-44% -$362K ﹤0.01% 1274
2021
Q1 		$1.69M Buy
+27,325
New +$1.85M ﹤0.01% 1047

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
Federated Hermes
Federated Hermes Pittsburgh, Pennsylvania $61.5B AUM 30.7% 1-Year Est. Return
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.11B AUM 171.34% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
KPF
K2 Principal Fund Toronto, Ontario, Canada $1.43B AUM 29.56% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return

Schroder Investment Management Group's AVIR Position: Q2 2022 in Review

Schroder Investment Management Group sold out of Atea Pharmaceuticals (AVIR) in Q2 2022, closing a stake of 104,789 shares — an estimated $742K sold.

Schroder Investment Management Group first reported a position in AVIR in Q1 2021 and held it in 5 quarters. The position peaked at $13.8M in Q4 2021. 127 funds tracked by Wall St. Rank hold AVIR as of Q2 2022.

  • Schroder Investment Management Group reported no remaining Atea Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
  • Schroder Investment Management Group sold 104,789 Atea Pharmaceuticals shares in Q2 2022, an estimated $742K.
  • Schroder Investment Management Group first reported a position in Atea Pharmaceuticals in Q1 2021 and held it in 5 quarters.
  • Schroder Investment Management Group's Atea Pharmaceuticals position peaked at $13.8M in Q4 2021.
  • 127 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2022.

Based on Schroder Investment Management Group's 13F filing for Q2 2022, filed 11 Aug 2022.